Scott Bluni

Scott Bluni is an experienced intellectual property attorney focused on counseling clients in patent-related matters such as strategic portfolio development, infringement avoidance, due diligence, enforcement, licensing, and other technology transactions. Dr. Bluni leverages his experiences as a former patent examiner and chief intellectual property counsel at a large, international medtech corporation to bring a pragmatic, solution-based approach to his practice.

Dr. Bluni has been recognized by Chambers USA: America’s Leading Lawyers for Business, Super Lawyers Massachusetts, LMG Life Sciences, and Managing IP – IP Stars.

Dr. Bluni has extensive experience representing medtech and other life science clients, from emerging start-ups to multibillion-dollar corporations. He has counseled innovators and senior business management focused on developing medical technologies such as drug eluting devices, drug pumps, microbial detection, chromatography and spectrometry, heart valves and other cardiovascular implants, tissue ablation, neurostimulation, orthopedics, medical imaging, urological implants, cardiac surgery devices, embolic materials, powered prosthetics, and many others. Dr. Bluni has also represented pharmaceutical and biotechnology companies in strategic portfolio development, opinion matters, freedom to operate, and other areas. Outside of life science work, Dr. Bluni leverages his training as a materials scientist and engineer to represent clients in industries that include consumer products, packaging, construction, and robotics.

Prior to joining Goodwin, Dr. Bluni was the owner and managing principal of Kacvinsky Daisak Bluni, an intellectual property boutique firm. Prior to KDB, Dr. Bluni was a partner and co-chair of the intellectual property group at Bingham McCutchen, an international general practice law firm. Previously, he was a Vice President, and Chief Intellectual Property Counsel at Boston Scientific Corporation. He began his legal career as a patent examiner at the United States Patent and Trademark Office.

Dr. Bluni has received numerous recognitions including a Chambers Band 4 IP Attorney ranking (2017-2024); Super Lawyers Massachusetts (2020-2021); America’s Leading Lawyers For Business: Massachusetts; Managing IP: Global IP Star (2018), Legal 500 US for Patents: Prosecution (2023); and LMG Life Sciences: Life Sciences Star.

Chambers USA recognizes Dr. Bluni as “extremely hard-working and responsive,” and having "fantastic practical business instincts as well as strong legal skills.”

Dr. Bluni’s publications include:

• Author, “CareDx v. Natera: The Latest in Patent Eligibility of Medical Diagnostics,” IP Watchdog, October 13, 2021
• Co-Author, “Understanding Medical Diagnostic Method Patent Eligibility,” Med Device Online, July 31, 2019
• Co-Author, “Mission Product Oral Argument Promises Certainty on Long Unresolved Question,” IPWatchdog, February 25, 2019